Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports

Nai-Si Huang1, Jia-Ying Chen1, Yan Meng2

  • 1Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.

Oral Oncology
|September 22, 2024
PubMed
Summary

Pralsetinib shows promise as a neoadjuvant treatment for locally advanced RET-fusion positive papillary thyroid cancer (PTC). This targeted therapy may improve surgical outcomes for patients with unresectable tumors.